EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

[cafead]

via Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US market and chasing down rival drugs from Astellas and Novartis.

article source